Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 285,600 shares, a drop of 31.9% from the April 30th total of 419,500 shares. Based on an average daily volume of 2,930,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.5% of the shares of the company are sold short.
Theratechnologies Stock Performance
Shares of NASDAQ THTX traded down $0.02 during mid-day trading on Thursday, reaching $2.63. The company had a trading volume of 93,146 shares, compared to its average volume of 808,066. Theratechnologies has a one year low of $1.12 and a one year high of $3.13. The firm has a market cap of $120.70 million, a price-to-earnings ratio of -26.25 and a beta of 0.56. The business's 50-day simple moving average is $2.38 and its 200 day simple moving average is $1.88.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of THTX. JPMorgan Chase & Co. acquired a new stake in shares of Theratechnologies during the fourth quarter valued at about $33,000. Raymond James Financial Inc. acquired a new stake in shares of Theratechnologies during the fourth quarter valued at about $27,000. Wealthspire Advisors LLC boosted its stake in shares of Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock valued at $129,000 after purchasing an additional 20,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Theratechnologies during the fourth quarter valued at about $40,000. Finally, Harbour Investments Inc. boosted its stake in shares of Theratechnologies by 20.0% during the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock valued at $159,000 after purchasing an additional 14,655 shares in the last quarter.
Wall Street Analyst Weigh In
Several research analysts have weighed in on THTX shares. Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th. Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a research report on Friday, February 14th.
Get Our Latest Stock Analysis on THTX
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
